Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA) has announced its management team's participation in three upcoming investor conferences. The company will attend the Guggenheim Healthcare Innovation Conference in Boston on November 13, 2024, with a fireside chat at 9:00 AM ET, the Jefferies London Healthcare Conference on November 19, 2024, at 1:30 PM GMT, and the 7th Annual Evercore HealthCONx Conference in Miami on December 5, 2024, at 10:00 AM ET. Live webcasts and recordings will be accessible through the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CNTA gained 1.40%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Guggenheim Healthcare Innovation Conference
Date: November 13, 2024
Location: Boston, MA
Fireside Chat: 9:00 AM ET
Event: Jefferies London Healthcare Conference
Date: November 19, 2024
Location: London, UK
Fireside Chat: 1:30 PM GMT
Event: 7th Annual Evercore HealthCONx Conference
Date: December 5, 2024
Location: Miami, FL
Fireside Chat: 10:00 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
FAQ
What investor conferences will Centessa Pharmaceuticals (CNTA) attend in November-December 2024?
Where can I watch Centessa Pharmaceuticals (CNTA) investor conference webcasts in 2024?
What time is Centessa Pharmaceuticals' (CNTA) presentation at the Guggenheim Healthcare Conference 2024?
